DPO: Rendering More Dialysis Patients with Higher Hb Levels

H2 tag- SEO Purpose

DPO: Rendering More Dialysis Patients with Higher Hb Levels, CKD: Chronic kidney disease; CV: Cardiovascular; DPO: Darbepoetin Alfa; ESA: Erythropoiesis-stimulating agent; IV: intravenous; Hb: Hemoglobin; SC: Subcutaneous.

Cresp logo
Darbepoetin Alfa offers a better approach to managing anemia in dialysis patients
Cost Savings
23%–36% reduction in ESA costs per patient.

23%–36% reduction in ESA costs per patient.

Estimated 230 hours saved per dialysis center per year.

Estimated 230 hours saved per dialysis center per year.

Clinical Evidence
23%–36% reduction in ESA costs per patient.
  • Comparable efficacy with both i.v. and s.c. administration routes with Darbepoetin Alfa in dialysis patients.
  • 25% dose reduction observed when switching from Epoetin to Darbepoetin Alfa.
  • Darbepoetin Alfa in dialysis patients has potential for reduced ESA-associated CV risk due to lower total doses.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cresp 2

Cresp®(Biosimilar of darbepoetin alpha), a product by Dr. Reddy's is an erythropoiesis-stimulating agent which helps in treatment of renal anemia in pre-dialysis patients

Cresp